Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study
Open Access
- 23 August 2018
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 36 (35), 5309-5317
- https://doi.org/10.1016/j.vaccine.2018.07.016
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Emerging experience with meningococcal serogroup B protein vaccinesExpert Review of Vaccines, 2017
- Meningococcal serogroup B vaccines: Estimating breadth of coverageHuman Vaccines & Immunotherapeutics, 2016
- The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal VaccinesJournal of Adolescent Health, 2016
- Meningococcal VaccinationsInfectious Diseases and Therapy, 2016
- Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B diseaseVaccine, 2016
- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015Published by Centers for Disease Control MMWR Office ,2015
- Bivalent rLP2086 Vaccine (Trumenba®): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10–25 YearsBioDrugs, 2015
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development ProgramDrugs, 2013
- Global epidemiology of invasive meningococcal diseasePopulation Health Metrics, 2013
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigensVaccine, 2012